Pharmacokinetics News and Research

RSS
The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Further Reading

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

11 Jan 2011
Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

11 Jan 2011
Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia

Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia

10 Jan 2011
Positive PK study results from ECLIPSE trial against cardiovascular disease

Positive PK study results from ECLIPSE trial against cardiovascular disease

10 Jan 2011
Positive results form INX-189 Phase 1b trial against hepatitis C virus

Positive results form INX-189 Phase 1b trial against hepatitis C virus

10 Jan 2011
Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen

Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen

7 Jan 2011
Chimerix initiates enrollment in CMX001 clinical study for life-threatening conditions caused by dsDNA viruses

Chimerix initiates enrollment in CMX001 clinical study for life-threatening conditions caused by dsDNA viruses

7 Jan 2011
BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

7 Jan 2011
Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

7 Jan 2011
ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly

ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly

7 Jan 2011
Nippon Kayaku begins apaziquone Phase 1 bladder cancer study in Japan

Nippon Kayaku begins apaziquone Phase 1 bladder cancer study in Japan

7 Jan 2011
MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

6 Jan 2011
Positive topline results from ZGN-433 Phase 1b study in obesity patients

Positive topline results from ZGN-433 Phase 1b study in obesity patients

6 Jan 2011
Insite Vision announces completion of patient enrollment in ISV-303 Phase 1/2 trial for post surgical ocular pain, inflammation

Insite Vision announces completion of patient enrollment in ISV-303 Phase 1/2 trial for post surgical ocular pain, inflammation

6 Jan 2011
SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

5 Jan 2011
Alnylam presents ALN-VSP Phase I trial results for liver cancer

Alnylam presents ALN-VSP Phase I trial results for liver cancer

5 Jan 2011
Vaccinex receives FDA clearance to initiate VX15/2503 Phase 1 clinical trial in advanced solid tumors

Vaccinex receives FDA clearance to initiate VX15/2503 Phase 1 clinical trial in advanced solid tumors

5 Jan 2011
FDA approves 200 mg formulation of INTELENCE for HIV-1

FDA approves 200 mg formulation of INTELENCE for HIV-1

3 Jan 2011
Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

28 Dec 2010
Transition, Elan to modify collaboration agreement for development, commercialization of ELND005

Transition, Elan to modify collaboration agreement for development, commercialization of ELND005

27 Dec 2010

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback